- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma


Major changes at Curaxis

Curaxis is to replace the majority of its Board of Directors and its executive management team in an attempt to better position the company for its next phase of growth and development.

Existing members of the Board have resigned from their officer positions and will be replaced by newly appointed members which bring more than 175 years of experience within the industry.

Patrick Smith, outgoing Chairman, says the company is honoured the “highly experienced and esteemed industry veterans” have joined the board and management team.

Mr Timothy Wright, Terence Novak, Michael George, Michael Miller, Ivan Gothner and Stephen Leary will all be joining the Board.  Dr Bert Spilker is the only existing Board member who will retain his position.

The company aims to be a leader in the treatment of Alzheimer’s disease with its drug candidate Memryte. It hopes the new team will bolster the drug’s movement to eventual commercialisation.

“We thank the departing Board and management for their efforts on behalf of the Company and its shareholders, and are very excited to develop Curaxis’ Alzheimer’s disease drug candidate and other pipeline candidates,” said Mr Timothy Wright, the newly appointed Chairman of the Board. 

“We are also pleased that Dr. Spilker will continue on the Board, as his extensive experience in clinical trials is a tremendous asset as the Company moves toward commercialization of Memryte.”

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription